Related Experiment Video
Updated: Mar 27, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
1.3K
Targeting the epithelium in pulmonary fibrosis
Muriel Lizé1, Christoph H Mayr1, Marina Bleck2
1Boehringer Ingelheim Pharma GmbH and Co. KG, Immunology and Respiratory Disease Research, Biberach an der Riß, Germany.
Summary
Idiopathic pulmonary fibrosis (IPF) research is exploring novel epithelial cell targets beyond fibroblasts. New "omic" technologies and models are identifying these targets for future IPF therapies.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Genomics
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung scarring disease.
- Current therapies like nintedanib and pirfenidone target fibroblasts but leave unmet needs.
- Recent research highlights novel epithelial cell populations in IPF pathogenesis.
Purpose of the Study:
- To review advances in "omic" technologies and functional cell systems for IPF research.
- To explore novel in vivo models and computational methods for disease relevance.
- To connect identified epithelial populations to potential therapeutic targets and biomarkers.
Main Methods:
- Review of single-cell sequencing and spatial profiling technologies.
- Analysis of functional co-culture studies and in vivo models.
- Application of computational gene set enrichment analysis for disease relevance.
Main Results:
- Identification of novel disease-associated epithelial cell populations in IPF.
- Understanding the role of cellular crosstalk in lung homeostasis and disease.
- Linking advanced technologies to clinically relevant biomarkers.
Conclusions:
- Epithelial cell populations represent promising targets for next-generation IPF therapeutics.
- Integration of "omic" data, spatial profiling, and functional models is crucial.
- Cutting-edge technologies are essential for validating new therapeutic strategies in IPF.
